Source: Annual Congress 2005 - Treatment of respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
O. Rajas, J. Aspa, C. De las Cuevas, B. Buendia, E. Antón, A. Casanova, J. García Gonzalez, E. Pérez Amor, J. Ancochea (Madrid, Spain). Evolution of antimicrobial resistance trends in the last five years in patients with bacteremic Pneumococcal community-acquired pneumonia (CAP-SP). Eur Respir J 2005; 26: Suppl. 49, 4056

Member's Comments

No comment yet.

Related content which might interest you: Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Changes in pathogens and pneumococcal serotypes causing community-acquired pneumonia in The Netherlands Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Prognostic score systems and community-acquired bacteraemic pneumococcal pneumonia Source: Eur Respir J 2006 Oct 01;28(4):816-823 Year: 2006 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Etiology and antibiotic resistance patterns in adults with severe community-acquired pneumonia in Russia Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia Source: Eur Respir J 2007; 30: 517-524 Year: 2007 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 A study of the prevalence of streptococcus pneumoniae serotypes in patients hospitalised for community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Prevalence of atypical bacterial pathogens in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008